Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

New biologic agents targeting interleukin (IL)23/T‐helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate‐to‐severe psoriasis over a 28‐week treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldarola, Giacomo, Galluzzo, Marco, Bernardini, Nicoletta, Calabrese, Laura, Grimaldi, Marta, Moretta, Gaia, Pagnanelli, Gianluca, Shumak, Ruslana Gaeta, Talamonti, Marina, Tofani, Lorenzo, Pallotta, Sabatino, Peris, Ketty, Potenza, Concetta, De Simone, Clara, Campione, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287013/
https://www.ncbi.nlm.nih.gov/pubmed/35384168
http://dx.doi.org/10.1111/dth.15488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287013/
https://www.ncbi.nlm.nih.gov/pubmed/35384168
http://dx.doi.org/10.1111/dth.15488

Ejemplares similares